{"id":15412,"date":"2023-08-03T10:28:00","date_gmt":"2023-08-03T02:28:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15412"},"modified":"2024-11-28T10:34:44","modified_gmt":"2024-11-28T02:34:44","slug":"siemens-healthineers-reports-3-6-yoy-revenue-growth-in-q3-2023-financials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15412","title":{"rendered":"Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials"},"content":{"rendered":"\n<p>Germany-based life sciences giant Siemens Healthineers AG (<a href=\"https:\/\/www.google.com\/finance\/quote\/SHL:ETR\">ETR: SHL<\/a>) has released its financial results for the third quarter of its 2023 fiscal year, which ended on June 30. The company reported global revenues of EUR 5.2 billion (USD 5.6 billion), marking a 3.6% year-on-year (YOY) growth in constant exchange rate terms. Excluding the loss of COVID-19 antigen testing revenues, the growth rate was a more robust 10.1% YOY.<\/p>\n\n\n\n<p><strong>Business Unit Performance and Regional Revenues<\/strong><br>By business unit, Imaging sales saw a significant increase of 15.2%, reaching EUR 2.86 billion (USD 3.14 billion). Diagnostics revenues, however, declined by 20.1% YOY to EUR 1.09 billion (USD 1.2 billion), reflecting the reduced demand for COVID-19 testing. Radiation oncology-focused Varian revenues increased by 6.7% YOY to EUR 840 million (USD 921 million), and Advanced Therapies grew revenues by 11.9% YOY to EUR 483 million (USD 530 million).<\/p>\n\n\n\n<p><strong>China and Europe as Key Growth Drivers<\/strong><br>In terms of regional revenues, Europe, CIS, Africa, the Middle East, and China were the primary growth drivers during Q3. China stood out as Siemens\u2019 fastest-growing region with a 17% YOY expansion to EUR 711 million (USD 780 million). For the Q1-Q3 period, China maintained its position as the fastest-growing region with an 11% increase to EUR 2.1 billion (USD 2.3 billion).<\/p>\n\n\n\n<p><strong>Revenue Growth in China and Impact of Anti-Corruption Campaign<\/strong><br>In China, Imaging and Advanced Therapies units experienced sharp revenue growth in Q3, while Diagnostics declined due to the absence of COVID testing revenues. CEO Bernhard Montag commented on the China market during the earnings conference call, noting that \u201cunderlying demand is super strong.\u201d Montag anticipates continued growth in the region in the high-single-digits or low-double-digits. However, he acknowledged potential disruption this year due to the government\u2019s anti-corruption campaign, which may cause hesitation in hospitals to place orders. Montag views any such disruption as a temporary phenomenon.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Germany-based life sciences giant Siemens Healthineers AG (ETR: SHL) has released its financial results for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[1555,27,223],"class_list":["post-15412","post","type-post","status-publish","format-standard","hentry","category-company","tag-etr-shl","tag-finanical-reports","tag-siemens-healthineers"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Germany-based life sciences giant Siemens Healthineers AG (ETR: SHL) has released its financial results for the third quarter of its 2023 fiscal year, which ended on June 30. The company reported global revenues of EUR 5.2 billion (USD 5.6 billion), marking a 3.6% year-on-year (YOY) growth in constant exchange rate terms. Excluding the loss of COVID-19 antigen testing revenues, the growth rate was a more robust 10.1% YOY.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15412\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15412\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-03T02:28:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-28T02:34:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15412#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15412\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials\",\"datePublished\":\"2023-08-03T02:28:00+00:00\",\"dateModified\":\"2024-11-28T02:34:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15412\"},\"wordCount\":299,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ETR: SHL\",\"Finanical Reports\",\"Siemens Healthineers\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15412#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15412\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15412\",\"name\":\"Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-03T02:28:00+00:00\",\"dateModified\":\"2024-11-28T02:34:44+00:00\",\"description\":\"Germany-based life sciences giant Siemens Healthineers AG (ETR: SHL) has released its financial results for the third quarter of its 2023 fiscal year, which ended on June 30. The company reported global revenues of EUR 5.2 billion (USD 5.6 billion), marking a 3.6% year-on-year (YOY) growth in constant exchange rate terms. Excluding the loss of COVID-19 antigen testing revenues, the growth rate was a more robust 10.1% YOY.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15412#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15412\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15412#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials - Insight, China&#039;s Pharmaceutical Industry","description":"Germany-based life sciences giant Siemens Healthineers AG (ETR: SHL) has released its financial results for the third quarter of its 2023 fiscal year, which ended on June 30. The company reported global revenues of EUR 5.2 billion (USD 5.6 billion), marking a 3.6% year-on-year (YOY) growth in constant exchange rate terms. Excluding the loss of COVID-19 antigen testing revenues, the growth rate was a more robust 10.1% YOY.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15412","og_locale":"en_US","og_type":"article","og_title":"Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15412","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-03T02:28:00+00:00","article_modified_time":"2024-11-28T02:34:44+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15412#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15412"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials","datePublished":"2023-08-03T02:28:00+00:00","dateModified":"2024-11-28T02:34:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15412"},"wordCount":299,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ETR: SHL","Finanical Reports","Siemens Healthineers"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15412#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15412","url":"https:\/\/flcube.com\/?p=15412","name":"Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-03T02:28:00+00:00","dateModified":"2024-11-28T02:34:44+00:00","description":"Germany-based life sciences giant Siemens Healthineers AG (ETR: SHL) has released its financial results for the third quarter of its 2023 fiscal year, which ended on June 30. The company reported global revenues of EUR 5.2 billion (USD 5.6 billion), marking a 3.6% year-on-year (YOY) growth in constant exchange rate terms. Excluding the loss of COVID-19 antigen testing revenues, the growth rate was a more robust 10.1% YOY.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15412#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15412"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15412#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15412"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15412\/revisions"}],"predecessor-version":[{"id":15413,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15412\/revisions\/15413"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}